<unk>  is an epidermal growth factor receptor (EGFR) antagonist that is FDA approved for the treatment of patients with metastatic squamous non-small cell lung cancer (first-line treatment in combination with gemcitabine and cisplatin). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include rash and hypomagnesemia (≥30%).
Necitumumab
Panitumumab
Cetuximab
Encorafenib
Dasatinib
Neratinib
Erdafitinib
Dabrafenib mesylate